uniQure to Submit BLA for Huntington's Disease Gene Therapy AMT-130 in Q3 2026 After Positive FDA Meeting

summarizeSummary

uniQure plans to submit a Biologic License Application (BLA) for its Huntington's disease gene therapy, AMT-130, in Q3 2026, following FDA agreement that Phase I/II data can support accelerated approval.

check_boxKey Events · Product Development and Regulatory · QURE

• BLA Submission Plan for AMT-130

  uniQure N.V. announced its plan to submit a Biologic License Application (BLA) for AMT-130 in Huntington's Disease during the third quarter of 2026.

• FDA Accepts Phase I/II Data for Accelerated Approval Basis

  The FDA communicated that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis for accelerated approval of AMT-130.

• Confirmatory Study Design Alignment Required

  Prior to BLA submission, the FDA seeks alignment on the confirmatory study design, including consideration of a concurrent control of standard of care without a sham procedure.

• Existing Regulatory Designations

  AMT-130 has previously been granted Regenerative Medicine Advanced Therapy (RMAT), Breakthrough Therapy, and Fast Track designations by the FDA.

auto_awesomeAnalysis · QURE · Life Sciences

This is a critical positive development for uniQure's lead gene therapy candidate, AMT-130, for Huntington's Disease. The FDA's agreement to accept Phase I/II study data as the primary basis for an accelerated approval Biologic License Application (BLA) significantly de-risks the regulatory pathway and accelerates the potential timeline to market. While alignment on a confirmatory study design is still needed, this is a standard requirement for accelerated approvals and the FDA has committed to working expeditiously. This news provides a strong counter-signal to recent negative events, including a securities fraud lawsuit and an FDA setback for another candidate (AMT-191).